Predictors of non-adherence to systemic oral therapy for advanced hepatocellular carcinoma

References

• Bray F, Ren JS, Masuyer E, et al. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer 2013;132:1133-45
   PubMed Web of Science ®Google Scholar
• Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917
   PubMed Web of Science ®Google Scholar
• Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-2
   PubMed Web of Science ®Google Scholar
• Lang L. FDA approves sorafenib for patients with inoperable liver cancer. Gastroenterology 2008;134:379
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90
   PubMed Web of Science ®Google Scholar
• Caraglia M, Giuberti G, Marra M, et al. Oxidative stress and ERK1/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with sorafenib plus octreotide LAR. Cell Death Dis 2011;2:e150
   PubMed Web of Science ®Google Scholar
• Marra M, Sordelli IM, Lombardi A, et al. Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview. J Translational Med 2011;9:171
   PubMed Web of Science ®Google Scholar
• Prete SD, Montella L, Caraglia M, et al. Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study. Cancer Chemother Pharmacol 2010;66:837-44
   PubMed Web of Science ®Google Scholar
• Bordonaro S, Raiti F, Di Mari A, et al. Active home-based cancer treatment. J Multidiscip Healthc 2012;5:137-43
   PubMedGoogle Scholar
• Noens L, van Lierde MA, De Bock R, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 2009;113:5401-11
   PubMed Web of Science ®Google Scholar
• McCowan C, Shearer J, Donnan PT, et al. Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer 2008;99:1763-8
   PubMed Web of Science ®Google Scholar
• Doti C, Stemmelin G, Shanley C, et al. Cytogenetic response in relation to the adherence to treatment with imatinib mesylage: a case control study. Blood 2007;110:Abstract 4553
   Web of Science ®Google Scholar
• Dezentje VO, van Blijderveen NJ, Gelderblom H, et al. Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer. J Clin Oncol 2010;28:2423-9
   PubMed Web of Science ®Google Scholar
• Bazeos A, Khorasbad J, Mahon FX, et al. Long term adherence to imatinib therapy is the critical factor for achieving molecular responses in chronic myeloid leukemia patients. Blood 2009;114:Abstract 3290
   Web of Science ®Google Scholar
• Wu EQ, Johnson S, Beaulieu N, et al. Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients. Curr Med Res Opin 2010;26:61-9
   PubMed Web of Science ®Google Scholar
• Partridge AH, Wang PS, Winer EP, et al. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 2003;21:602-6
   PubMed Web of Science ®Google Scholar
• Atkins L, Fallowfield L. Intentional and non-intentional non-adherence to medication amongst breast cancer patients. Eur J Cancer 2006;42:2271-6
   PubMed Web of Science ®Google Scholar
• Kahn KL, Schneider EC, Malin JL, et al. Patient centered experiences in breast cancer: predicting long-term adherence to tamoxifen use. Med Care 2007;45:431-9
   PubMed Web of Science ®Google Scholar
• Hershman DL, Kushi LH, Shao T, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8769 early-stage breast cancer patients. J Clin Oncol 2010;28:4120-8
   PubMed Web of Science ®Google Scholar
• Sedjo RL, Devine S. Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer. Breast Cancer Res Treat 2011;125:191-200
   PubMed Web of Science ®Google Scholar
• Lash TL, Fox MP, Westrup JL, et al. Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat 2006;99:215-20
   PubMed Web of Science ®Google Scholar
• StCharles M, Bollu VK, Hornyak E, et al. Predictors of treatment non-adherence in patients treated with imatinib mesylate for chronic myeloid leukemia. Blood 2009;114:Abstract 2209
   Web of Science ®Google Scholar
• Streeter SB, Schwartzberg L, Husain N, Johnsrud M. Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions. J Oncol Pract 2011;7:46-51s
   PubMedGoogle Scholar
• Charlson JA, Hedin T, Sparapani C, et al. Early discontinuation of tamoxifen and aromatase inhibitors (AI) by postmenopausal women with early-stage breast cancer. ASCO Meeting Abstracts 2012:524
   Google Scholar
• Winterhalder R, Hoesli P, Delmore G, et al. Self-reported compliance with capecitabine: findings from a prospective cohort analysis. Oncology 2011;80:29-33
   PubMed Web of Science ®Google Scholar
• Bazeos A, Khorasbad J, Mahon FX, et al. Long term adherence to imatinib therapy is the critical factor for achieving molecular responses in chronic myeloid leukemia patients. Blood 2006;114:Abstract 3290
   Google Scholar
• Klein CE, Kastrissios H, Miller AA, et al. Pharmacokinetics, pharmacodynamics and adherence to oral topotecan in myelodysplastic syndromes: a Cancer and Leukemia Group B study. Cancer Chemother Pharmacol 2006;57:199-206
   PubMed Web of Science ®Google Scholar
• Lee CR, Nicholson PW, Ledermann JA, et al. Patient compliance with prolonged oral altretamine treatment in relapsed ovarian cancer. Eur J Gynaecol Oncol 1996;17:99-103
   PubMedGoogle Scholar
• Partridge AH, Archer L, Kornblith AB, et al. Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104. J Clin Oncol 2010;28:2418-22
   PubMed Web of Science ®Google Scholar
• Arkana C, Ingemi MC, Guerrera M, et al. ‘Impakt’ of oral therapies on metastatic breast cancer patients. Combination of oral capecitabine and vinorelbine. Ann Oncol Suppl 2011;2:ii62
   Google Scholar
• Dickens AJ, Twelves CJ. Tablet burden in women with metastatic breast cancer: Implications for clinical practice. Eur J Cancer 2009;7(Suppl 2–3):274
   Google Scholar
• Grunfeld EA, Hunter MS, Sikka P, et al. Adherence beliefs among breast cancer patients taking tamoxifen. Patient Educ Couns 2005;59:97-102
   PubMed Web of Science ®Google Scholar
• Fedele P, Nacci A, Orlando L, et al. Adherence to and persistence with an oral metronomic chemotherapy with capecitabine in heavily pretreated metastatic breast cancer (MBC) patients. Ann Oncol 2010;21(Suppl 8):361
   Google Scholar
• Kirk MC, Hudis CA. Insight into barriers against optimal adherence to oral hormonal therapy in women with breast cancer. Clin Breast Cancer 2008;8:155-61
   PubMed Web of Science ®Google Scholar
• Mayer EL, Partridge AH, Harris LN, et al. Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer. Breast Cancer Res Treat 2009;117:615-23
   PubMed Web of Science ®Google Scholar
• Ziller V, Kalder M, Albert US, et al. Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann Oncol 2009;20:431-6
   PubMed Web of Science ®Google Scholar
• Chan A, Leow YC, Sim MH. Patients’ perspectives and safe handling of oral anticancer drugs at an Asian cancer center. J Natl Compr Canc Netw 2009;15:161-5
   Google Scholar
• Decker V, Spoelstra S, Miezo E, et al. A pilot study of an automated voice response system and nursing intervention to monitor adherence to oral chemotherapy agents. Cancer Nurs 2009;32:E20-9
   PubMed Web of Science ®Google Scholar
• Partridge AH, Avorn J, Wang PS, et al. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst 2002;94:652-61
   PubMed Web of Science ®Google Scholar
• Jasti S, Siega-Riz AM, Cogswell ME, et al. Correction for errors in measuring adherence to prenatal multivitamin/mineral supplement use among low-income women. J Nutr 2006;136:479-83
   PubMed Web of Science ®Google Scholar
• Huiart L, Dell’Aniello S, Suissa S. Use of tamoxifen and aromatase inhibitors in a large population-based cohort of women with breast cancer. Br J Cancer 2011;104:1558-63
   PubMed Web of Science ®Google Scholar
• Partridge AH, LaFountain A, Mayer E, et al. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 2008;26:556-62
   PubMed Web of Science ®Google Scholar
• Rey-Herin D, Bouhnik AD, Cortaredona S, et al. Low adherence to long-term adjuvant endocrine therapy in breast cancer women age 40 or younger. J Clin Oncol 2010;28(15 Suppl):643
   Google Scholar
• Karve S, Cleves MA, Helm M, et al. Prospective validation of eight different adherence measures for use with administrative claims data among patients with schizophrenia. Value Health 2009;12:989-95
   PubMed Web of Science ®Google Scholar
• Nexavar (sorafenib) Prescribing Information. Wayne, NJ: Bayer Healthcare Pharmaceuticals Inc., 2012
   Google Scholar
• Schulman KL, Berenson K, Shih YC, et al. A checklist for as+certaining study cohorts in oncology health services research using secondary data: Report of the ISPOR oncology good outcomes research practices working group. Value Health 2013;16:655--69
   Google Scholar
• Wood L. Managing the side effects of sorafenib and sunitinib. Community Oncol 2006;3:558-62
   Google Scholar
• Kane RC, Farrell AT, Madabushi R, et al. Sorafenib for the treatment of unresectable hepatocellular carcinoma. Oncologist 2009;14:95-100
   PubMed Web of Science ®Google Scholar
• Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-97
   PubMed Web of Science ®Google Scholar
• Grant RW, O’Leary KM, Weilburg JB, et al. Impact of concurrent medication use on statin adherence and refill persistence. Arch Intern Med 2004;164:2343-8
   PubMed Web of Science ®Google Scholar
• George J, Shalansky SJ. Predictors of refill non-adherence in patients with heart failure. Br J Clin Pharmacol 2007;63:488-93
   PubMed Web of Science ®Google Scholar
• Iavarone M, Cabibbo G, Piscaglia F, et al. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology 2011;54:2055-63
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Geller ML. Adherence to endocrine therapy for breast cancer. Oncology 2006;71:1-9
   PubMed Web of Science ®Google Scholar
• Demissie S, Silliman RA, Lash TL. Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. J Clin Oncol 2001;19:322-8
   PubMed Web of Science ®Google Scholar
• Vincenzi B, Santini D, Russo A, et al. Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. Oncologist 2010;15:85-92
   PubMed Web of Science ®Google Scholar
• Becker MH. Socio-behavioral determinants of compliance. Baltimore, MD: The Johns Hopkins University Press, 1976
   Google Scholar
• Bandura A. Self-efficacy: toward a unifying theory of behavioral change. Psychol Rev 1977;84:191-215
   PubMed Web of Science ®Google Scholar
• Kehoe WA, Katz RC. Health behaviors and pharmacotherapy. Ann Pharmacother 1998;32:1076-86
   PubMed Web of Science ®Google Scholar
• Goldman DP, Joyce GF, Escarce JJ, et al. Pharmacy benefits and the use of drugs by the chronically ill. JAMA 2004;291:2344-50
   PubMed Web of Science ®Google Scholar
• Levine AM, Richardson JL, Marks G, et al. Compliance with oral drug therapy in patients with hematologic malignancy. J Clin Oncol 1987;5:1469-76
   PubMed Web of Science ®Google Scholar